Express News | NLS Pharmaceutics AG - Additional Bridge Loan Addendums Providing for Extension of Maturity Date Under Each of Loan Agreements to June 30, 2025
NLS Pharmaceuticals — Additional Transitional Loan Addendum to the Transitional Loan Agreement dated November 15, 2023 signed on May 16
NLS Pharmaceuticals — Additional Transitional Loan Addendum to the Transitional Loan Agreement dated November 15, 2023 signed on May 16
Express News | NLS Pharmaceutics - on May 16, Entered Into Additional Bridge Loan Addendums to Bridge Loan Agreement Dated Nov 15, 2023
20-F: Registration statement / Annual report / Transition report
NLS Pharmaceutics Receives Nasdaq Staff Delisting Determination
NLS Pharmaceutics Ltd Strategizes for Growth
Board Member Resigns From NLS Pharmaceutics Ltd.
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
NLS Pharmaceutics Ltd. Announces New Warrant Issue
NLS Pharmaceutics Ltd. Addresses Financial Claims
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
NLS Pharmaceutics Expands Neurological Therapy Options
NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Secures Exclusive Global License For Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
NLS Pharmaceutics Extends Loan Maturity Date
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
NLS Pharmaceutics Announced Nasdaq Letter Related To Continued Listing Requirements
NLS Pharmaceutics Announced Nasdaq Letter Related To Continued Listing Requirements
Notice of Deficiency With Nasdaq Continued Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
NLS Pharmaceutics CEO Issues Letter to Shareholders
NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) today announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders.
No Data